- Home
- FORR vs HUMA Comparison
FORR vs HUMA Comparison
Compare FORR & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | HUMA |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 182.6M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | FORR | HUMA |
|---|---|---|
| Price | $6.30 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 95.2K | ★ 6.0M |
| Earning Date | 02-12-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,871,000.00 | $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $731.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.22 | $0.88 |
| 52 Week High | $15.26 | $4.14 |
Technical Indicators
Market Signals| Indicator | FORR | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 23.12 | 47.05 |
| Support Level | $6.22 | $0.96 |
| Resistance Level | $7.40 | $1.03 |
| Average True Range (ATR) | 0.41 | 0.10 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 2.05 | 30.49 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.